Pfizer, Biocon abort alliance as business differences outweigh [bio]similarities
This article was originally published in Scrip
Executive Summary
Pfizer and Biocon have aborted their alliance for biosimilar versions of insulin and insulin analogue products, though the Indian firm says that the separation is unlikely to hurt its near-term earnings. Both erstwhile partners said that in view of their "individual priorities" for their respective biosimilars businesses they would now move ahead independently.